Derivatives of benzodiazepines have long been known to be effective in treating anxiety disorders by altering the gamma-aminobutyric acid (GABA) pathway. Recent studies have highlighted their potential as novel antidepressants, providing a viable approach to treating the intricate systems that underlie depression. The mechanisms of action of benzodiazepine derivatives are examined in this review, with particular attention paid to how they interact with GABA receptors and how they might affect neurotrophic factors that are linked to depression. Clinical evidence is presented to illustrate the prospects and problems in this sector, as well as the antidepressant efficacy, safety profile, and comparison with standard antidepressants. The review also examines recently developed benzodiazepine analogs that have improved antidepressant qualities and fewer adverse effects, opening the door for new treatment approaches. Comprehending how benzodiazepine derivatives contribute to depression creates new opportunities for tailored and efficient medication for mood disorders.